JP5567756B2 - 粘膜感染症の処置のための組成物および方法 - Google Patents

粘膜感染症の処置のための組成物および方法 Download PDF

Info

Publication number
JP5567756B2
JP5567756B2 JP2001583799A JP2001583799A JP5567756B2 JP 5567756 B2 JP5567756 B2 JP 5567756B2 JP 2001583799 A JP2001583799 A JP 2001583799A JP 2001583799 A JP2001583799 A JP 2001583799A JP 5567756 B2 JP5567756 B2 JP 5567756B2
Authority
JP
Japan
Prior art keywords
composition
bacteria
microorganism
nthi
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001583799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003533489A (ja
JP2003533489A5 (enExample
Inventor
クランシー，ロバート・ルエリン
パン，ジェラルド
ダンクリー，マーガレット・ロレイン
Original Assignee
ハンター・イミュノロジー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンター・イミュノロジー・リミテッド filed Critical ハンター・イミュノロジー・リミテッド
Publication of JP2003533489A publication Critical patent/JP2003533489A/ja
Publication of JP2003533489A5 publication Critical patent/JP2003533489A5/ja
Application granted granted Critical
Publication of JP5567756B2 publication Critical patent/JP5567756B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001583799A 2000-05-19 2001-05-21 粘膜感染症の処置のための組成物および方法 Expired - Fee Related JP5567756B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU7612 1994-08-24
AUPQ7612A AUPQ761200A0 (en) 2000-05-19 2000-05-19 Compositions and methods for treatment of mucosal infections
AUPQ7612 2000-05-19
PCT/AU2001/000588 WO2001087332A1 (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012080832A Division JP2012153706A (ja) 2000-05-19 2012-03-30 粘膜感染症の処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2003533489A JP2003533489A (ja) 2003-11-11
JP2003533489A5 JP2003533489A5 (enExample) 2008-07-10
JP5567756B2 true JP5567756B2 (ja) 2014-08-06

Family

ID=3821690

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001583799A Expired - Fee Related JP5567756B2 (ja) 2000-05-19 2001-05-21 粘膜感染症の処置のための組成物および方法
JP2012080832A Pending JP2012153706A (ja) 2000-05-19 2012-03-30 粘膜感染症の処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012080832A Pending JP2012153706A (ja) 2000-05-19 2012-03-30 粘膜感染症の処置のための組成物および方法

Country Status (10)

Country Link
US (1) US8637051B2 (enExample)
EP (1) EP1305042B1 (enExample)
JP (2) JP5567756B2 (enExample)
KR (1) KR20030019389A (enExample)
CN (1) CN1437480A (enExample)
AT (1) ATE535284T1 (enExample)
AU (1) AUPQ761200A0 (enExample)
BR (1) BR0110971A (enExample)
CA (1) CA2409813C (enExample)
WO (1) WO2001087332A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
WO2005077409A1 (en) * 2004-02-18 2005-08-25 The University Of Newcastle Research Associates Limited A vaccine formulated for administration to mucosa of the lungs
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1793848A4 (en) * 2004-08-17 2008-06-11 Hunter Immunology Ltd METHOD OF DETERMINING A DOSAGE FOR ORAL INACTIVE VACCINE
ATE526978T1 (de) 2004-08-17 2011-10-15 Hunter Immunology Ltd Verfahren zur herstellung von oral abgetöteten vakzinen
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US8857659B2 (en) 2010-03-18 2014-10-14 Eveready Battery Company, Inc. Button cell battery dispenser package
EP2585094B1 (en) * 2010-06-25 2018-08-01 INSERM - Institut National de la Santé et de la Recherche Médicale Flagellin polypeptide as tlr5 agonist for use in the treatment of respiratory tract infections
US20140275420A1 (en) 2011-08-22 2014-09-18 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
CA3254723A1 (en) * 2014-05-02 2025-04-15 Qu Biologics Inc ANTIMICROBIAL IMMUNOMODULATION
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CN111529703B (zh) * 2020-06-17 2023-09-15 湖南循天然营养有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用
WO2024234034A1 (en) * 2023-05-12 2024-11-21 Biomune Pty Ltd Compositions and methods for preventative treatments for mucosal associated ailments

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
US6231870B1 (en) * 1995-06-02 2001-05-15 Uab Research Foundation Oral administration of pneumoccal antigens
JPH0680575A (ja) * 1991-03-05 1994-03-22 Meiji Milk Prod Co Ltd 経口免疫賦活剤
ES2262181T3 (es) 1996-05-31 2006-11-16 National University Of Ireland, Maynooth Il-12 como adyuvante en la vacuna contra la especie bordetella pertussis.
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
WO1999012416A1 (en) * 1997-09-09 1999-03-18 The Trustees Of Columbia University In The City Of New York T-independent conjugate-vaccines
US6153182A (en) 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
PL341697A1 (en) 1997-12-23 2001-04-23 Genesis Res & Dev Corp Ltd Compositions derived from mycobacterium vaccae and methods of using them
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
DE69942214D1 (de) 1998-02-05 2010-05-12 Glaxosmithkline Biolog Sa Verfahren zur Reinigung oder Herstellung der MAGE Protein
SE9800615D0 (sv) * 1998-02-27 1998-02-27 Ingvar Sjoeholm Mucosal microparticle conjugate vaccine
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
CN1298307A (zh) 1998-03-05 2001-06-06 俄亥俄医学院 通过鼻内接种il－12加强免疫性
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
EP1087788A1 (fr) * 1998-06-26 2001-04-04 Aventis Pasteur Immunisation a ciblage mucosal
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
EP1303300B1 (en) * 2000-06-19 2010-08-11 Hunter Immunology Limited Compositions and methods for treatment of candidiasis
NZ523995A (en) * 2000-08-08 2005-03-24 Genesis Res & Dev Corp Ltd Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them

Also Published As

Publication number Publication date
CA2409813A1 (en) 2001-11-22
BR0110971A (pt) 2005-04-05
JP2003533489A (ja) 2003-11-11
EP1305042A4 (en) 2005-02-02
WO2001087332A1 (en) 2001-11-22
EP1305042A1 (en) 2003-05-02
CN1437480A (zh) 2003-08-20
JP2012153706A (ja) 2012-08-16
EP1305042B1 (en) 2011-11-30
ATE535284T1 (de) 2011-12-15
US20040057965A1 (en) 2004-03-25
AUPQ761200A0 (en) 2000-06-15
CA2409813C (en) 2013-11-12
US8637051B2 (en) 2014-01-28
KR20030019389A (ko) 2003-03-06

Similar Documents

Publication Publication Date Title
JP2012153706A (ja) 粘膜感染症の処置のための組成物および方法
US20220257668A1 (en) Compositions comprising bacterial strains
US20030180260A1 (en) Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor
Matsuzaki et al. Modulating immune responses with probiotic bacteria
Matricardi et al. Microbial products in allergy prevention and therapy
Havenaar et al. Probiotics from an immunological point of view
US20130064885A1 (en) Probiotic products for pet applications
AU2007316091A1 (en) Prophylactic tuberculosis vaccine
JP2003533489A5 (enExample)
Srutkova et al. Exopolysaccharide from Lacticaseibacillus rhamnosus induces IgA production in airways and alleviates allergic airway inflammation in mouse model
Sánchez-Ramón et al. Extending the clinical horizons of mucosal bacterial vaccines: current evidence and future prospects
JP2007169200A (ja) インフルエンザ感染予防のための医薬及び飲食品
JP2008502606A (ja) 乳酸菌及び下痢の予防におけるそれらの使用
KR20110069102A (ko) 비피막형 헤모필루스 인플루엔자 백신 및 그의 용도
AU2001258060B2 (en) Compositions and methods for treatment of mucosal infections
AU2001258060A1 (en) Compositions and methods for treatment of mucosal infections
Lehtoranta Probiotics and immune modulation: reducing risk for cold and flu
Tanabe et al. Subinhibitory concentrations of tetracyclines induce lipopolysaccharide shedding by Porphyromonas gingivalis and modulate the host inflammatory response
CN100579581C (zh) 用于治疗分枝杆菌感染的组合物
Gut Anti-Salmonella Properties of Kefir and Kefir yeast isolates: Potential application in infection control and prevention
Munir et al. Generation of Protective Antibodies in Mice via Inactivated Whole-Cell Vaccine Targeting Multidrug-Resistant Escherichia coli
Kroeker et al. Treatment of Ulcerative Colitis
Yuan et al. Dose effects of LAB on modulation of rotavirus vaccine induced immune responses
AU2001265695A1 (en) Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
Shivakumar et al. Probiotics in Periodontology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080521

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140620

R150 Certificate of patent or registration of utility model

Ref document number: 5567756

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees